Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (891)	5/9/2002 8:28:51 PM
From: Boris2000	Respond to of 1139

Is ICOS stock under-valued or overpriced ? Look at it this way: the ENTIRE market cap valuation of this company ( at $ 24.50 /share ) is equivalent to about ONE years' gross sales revenue of Viagra - This market cap places ZERO valuation on the other drug candidates in the ICOS pipeline, nor any valuation of the company's multiple strategic partnerships with other Biotech leaders. Read past the headlines and look past the next six months - this stock will double within a year - IMHO......